<DOC>
	<DOC>NCT02388906</DOC>
	<brief_summary>The purpose of this study is to determine whether nivolumab is better than ipilimumab to prevent recurrence of melanoma.</brief_summary>
	<brief_title>Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma (CheckMate 238)</brief_title>
	<detailed_description>Italy, Greece, and Argentina: ≥ 18 years of age</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com At least 15 years of age Except: where local regulations and/or institutional policies do not allow for subjects &lt; 18 years of age (pediatric population) to participate. For those sites, the eligible subject population is ≥ 18 years of age Completely removed melanoma by surgery performed within 12 weeks of randomization Stage IIIb/C or Stage IV before complete resection No previous anticancer treatment Ocular or uveal melanoma History of carcinomatosis meningitis History of autoimmune disease Treatment directed against the resected melanoma that is administrated after the surgery</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>